Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunovant, Inc. (IMVT : NSDQ)
 
 • Company Description   
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.

Number of Employees: 362

 
 • Price / Volume Information   
Yesterday's Closing Price: $34.15 Daily Weekly Monthly
20 Day Moving Average: 2,462,792 shares
Shares Outstanding: 205.31 (millions)
Market Capitalization: $7,011.30 (millions)
Beta: 0.70
52 Week High: $36.29
52 Week Low: $13.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 18.13% 12.36%
12 Week 24.59% 15.18%
Year To Date 34.34% 23.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1000 PARK FORTY PLAZA
-
DURHAM,NC 27713
USA		 ph: 917-410-3120
fax: -		 info@immunovant.com http://www.mmunovant.com
 
 • General Corporate Information   
Officers
Eric Venker - Chief Executive Officer
Frank M. Torti - Executive Chairperson
Tiago Girao - Chief Financial Officer
Jacob Bauer - Director
Andrew Fromkin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258J102
SIC: 2836
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/10/26
Share - Related Items
Shares Outstanding: 205.31
Most Recent Split Date: (:1)
Beta: 0.70
Market Capitalization: $7,011.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.60 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.22
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -14.06%
vs. Previous Quarter: -19.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -65.66
12/31/25 - -63.17
09/30/25 - -81.55
ROA
03/31/26 - -59.88
12/31/25 - -58.01
09/30/25 - -73.09
Current Ratio
03/31/26 - 9.09
12/31/25 - 15.74
09/30/25 - 9.07
Quick Ratio
03/31/26 - -
12/31/25 - 15.74
09/30/25 - 9.07
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Book Value
03/31/26 - 4.15
12/31/25 - 5.63
09/30/25 - 2.98
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
 

Powered by Zacks Investment Research ©